United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Nilda Mesa sold 325 shares of the company's stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total value of $77,285.00. Following the sale, the director now owns 5,373 shares in the company, valued at $1,277,699.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $229.72 on Friday. The firm has a market cap of $10.81 billion, a PE ratio of 11.58 and a beta of 0.52. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $261.54. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. The business has a 50 day moving average price of $226.00 and a 200-day moving average price of $227.44.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts' consensus estimates of $4.28 by $0.08. The firm had revenue of $614.70 million during the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business's quarterly revenue was up 25.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.67 earnings per share. Equities research analysts predict that United Therapeutics Co. will post 23.46 earnings per share for the current year.
Analysts Set New Price Targets
Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI
From Banyan Hill Publishing | Ad
Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.”
Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.
Click on Adam's shiny forehead for more details.
UTHR has been the topic of several analyst reports. The Goldman Sachs Group upgraded United Therapeutics from a "sell" rating to a "neutral" rating and upped their price target for the company from $213.00 to $215.00 in a research report on Monday, February 12th. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Tuesday. HC Wainwright reiterated a "buy" rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. SVB Leerink assumed coverage on United Therapeutics in a research report on Monday, February 5th. They set an "outperform" rating and a $330.00 price target on the stock. Finally, Wedbush reissued an "outperform" rating and set a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $294.40.
Read Our Latest Stock Report on UTHR
Hedge Funds Weigh In On United Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. Wellington Management Group LLP raised its holdings in shares of United Therapeutics by 73.7% during the first quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company's stock valued at $300,585,000 after acquiring an additional 710,668 shares in the last quarter. Norges Bank bought a new position in United Therapeutics in the fourth quarter worth $100,519,000. BlackRock Inc. raised its holdings in United Therapeutics by 7.3% in the second quarter. BlackRock Inc. now owns 5,096,685 shares of the biotechnology company's stock worth $1,125,093,000 after purchasing an additional 344,724 shares in the last quarter. State Street Corp raised its holdings in United Therapeutics by 15.9% in the first quarter. State Street Corp now owns 1,795,102 shares of the biotechnology company's stock worth $402,031,000 after purchasing an additional 245,747 shares in the last quarter. Finally, Avidity Partners Management LP bought a new position in United Therapeutics in the fourth quarter worth $52,158,000. Institutional investors own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
